Datavault AI (NASDAQ: DVLT) announced a binding term sheet with Wellgistics Health (NASDAQ: WGRX) to create DelivMeds AI, a healthcare platform that integrates AI-driven pharmacy optimization, blockchain-enabled smart contracts, biometric verification, and direct-to-consumer healthcare delivery. The deal comprises three concurrent transactions: an expanded PharmacyChain(TM) license, acquisition of QOLPOM intellectual property, and a controlling stake in Tollo Health. The combined transactions carry an expected approximate asset value of $4 billion, subject to an independent fairness opinion, and are intended to support a national rollout of data-driven healthcare delivery and patient engagement solutions.
This collaboration leverages Datavault AI's expertise in AI-driven data experiences and monetization within the Web 3.0 environment. The company's cloud-based platform includes Acoustic Sciences and Data Science divisions, with technologies such as WiSA(R), ADIO(R), and Sumerian(R) for spatial audio, and the Information Data Exchange(R) for secure digital twins and licensing of name, image, and likeness. The platform serves industries including sports & entertainment, biotech, fintech, real estate, healthcare, and energy. For more details, the full press release is available at https://ibn.fm/yIVh9.
Datavault AI is headquartered in Philadelphia, PA, and is listed on NASDAQ under the ticker DVLT. The company's technology suite offers AI- and machine-learning-based automation, third-party integration, and detailed analytics. Investors can find the latest news and updates at the company's newsroom: https://ibn.fm/DVLT. The formation of DelivMeds AI represents a significant step in applying advanced technologies to healthcare, potentially transforming how pharmacy services are delivered and managed on a national scale.
